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A case of recurrent coronavirus disease 2019 (COVID-19) with neurovestibular symptoms
was reported. In March 2020, a physician working in an Italian pediatric hospital had
flu-like symptoms with anosmia and dysgeusia, and following a reverse transcription PCR
(RT/PCR) test with a nasopharyngeal swab tested positive for SARS-CoV-2. After home
quarantine, 21 days from the beginning of the symptoms, the patient tested negative in
two subsequent swabs and was declared healed and readmitted to work. Serological
testing showed a low level of immunoglobulin G (IgG) antibody title and absence of
immunoglobulin M (IgM). However, 2 weeks later, before resuming work, the patient
complained of acute vestibular syndrome, and the RT/PCR test with mucosal swab
turned positive. On the basis of the literature examined and reviewed for recurrence cases
and vestibular symptoms during COVID-19, to our knowledge this case is the first case
of recurrence with vestibular impairment as a neurological symptom, and we defined it as
probably a viral reactivation. The PCR retest positivity cannot differentiate re-infectivity,
relapse, and dead-viral RNA detection. Serological antibody testing and viral genome
sequencing could be always performed in recurrence cases.
Keywords: recurrence, occupational medicine, neuroCOVID, neurologic symptoms, vestibular syndrome,
healthcare workers, case report
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INTRODUCTION
In China, in December 2019, the epidemic caused by severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) rapidly
diffused all over the world leading to a pandemic. While the
coronavirus disease 2019 (COVID-19) typically presents as a
self-limiting respiratory disease, and in hospitalized patients,
the clinical picture is dominated by respiratory distress (Del
Sole et al., 2020), progression to severe illness with multiorgan
involvement, including the blood vessels, heart, gut, kidneys,
testicles, and brain has been reported (Asadi-Pooya and Simani,
2020; Chen X. et al., 2020; Ibrahim, 2020; Leonardi et al., 2020;
Nepal et al., 2020). Patients suffering from COVID-19 can
develop acute or long-term neurological sequelae (Ellul et al.,
2020). The prevalence of neuro-COVID varies considerably
between individual studies ranging from 4.1% (Xiong et al.,
2020) to 57.4% (Romero-Sánchez et al., 2020) and even 84%
in COVID-19 with acute respiratory distress syndrome (Helms
et al., 2020). The onset of nervous system damage can be
asynchronous with systemic manifestations and the typically
salient severe respiratory disease (Vavougios, 2020).
In our pediatric hospital, between March and May 2020,
there were 25 cases of COVID-19 among healthcare workers
(HCWs), equal to 1.1% of the total staff. Two of them had
at least one symptom, namely, headache, anosmia, and
dysgeusia or all the three symptoms at the same time.
These neurological symptoms indicate that the virus, like
other respiratory viruses (Bohmwald et al., 2018), enters the
central nervous system (CNS) through the olfactory bulb
causing inflammation. Furthermore, SARS-CoV-2 viruses
can spread from the mechano- and chemo-receptors in
the lungs and lower respiratory airways to the medullary
cardiorespiratory center via a synapse-connected route
(Li Y. C. et al., 2020).
In this study, we report a case of recurrent SARS-CoV-2
infection with neurovestibular involvement, review literature
cases with vestibular involvement, and discuss the neurotropism
of this virus based on literature data.
Case Description
A 48-year-old female physician in a pediatric hospital presented
cough, slight dyspnea, severe myalgia, asthenia, and headache
on March, 2020, followed by anosmia and dysgeusia over the
following few days (Figure 1) without fever. When symptoms
appeared the worker self-isolated at home. The allergic rhinitis
the patient suffers from led to a short delay in diagnosis;
however, a swab carried out 8 days from the beginning of
the symptoms tested positive for SARS-CoV-2 (AllplexTM2019-
nCoV Assay). In subsequent days, the patient felt better and
became asymptomatic. On days 23 and 27 the patient was
retested and was negative both times. On day 37, serology
was performed by ELISA and a low level of immunoglobulin
G (IgG) against SARS-CoV-2 was detected. Immunoglobulin
M (IgM) search was negative. She was feeling well and was
declared fit to work by the occupational physician of the hospital.
However, before returning to work, on day 39 the patient
woke up experiencing intensive dizziness, described as subjective
vertigo, associated with vomiting and bilateral aural fullness
(Figure 1). The dizziness quickly got worse as the patient lied
supine on the right side. She was transported by ambulance
to the emergency room of a hospital where dizzying syndrome
was diagnosed and treated with metoclopramide. Physical
examination revealed normal vital signs, while the patient was
breathing ambient air. Some relevant auxiliary examinations such
as blood routine, coagulation function, liver and renal function,
electrolytes, and inflammation indicators were completed, and
the results were normal. After 3 h and the improvement of the
symptoms, she was discharged home, cared by health public
service, and treated with betahistine dihydrochloride for 1 week.
The day after, on day 40, a nasal swab was obtained, which
tested positive.
In the following days, the dizziness disappeared and only a
mild postural instability persisted, whereas aural fullness was
unchanged. The only pathology that she suffered from was
allergic rhinitis. She had never suffered from dizziness in the past.
An ear, nose, and throat (ENT) visit took place on day
44. Otoscopy was negative. Romberg, Unterberger (March-in-
place), and finger-to-nose tests were negative. Neither bedside
vestibular examination with Frenzel glasses showed spontaneous
nystagmus, nor was nystagmus evoked by supine position, Dix-
Hallpike maneuver, lateral head rotation, and Rose position. The
head-shaking test was negative. The only relevant finding of the
vestibular examination was the patient complaining about slight
dizziness during the Dix-Hallpike maneuver on the right side
(supine position with the head hyperextended and tilted to the
right side). The patient did not develop fever both in the first
and in the second phase of the symptoms related to COVID-
19. Despite fever being one of the most common symptoms of
COVID-19, it may be absent in some individuals. Finally, the
patient was completely healed without any deficit and was able
to return to work.
DISCUSSION
The case reported presents numerous points of interest. First,
the recurring nature of the symptoms must be emphasized along
with the neurological origin of the symptoms themselves. Second,
the neurotropism and neuroinvasive potential of the virus into
recurrence mode should be considered. Finally, the observation
that the presence of anti-spike IgG has been followed by a positive
PCR test; this feature is rather infrequent, having been found in
0.13 per 10,000 days at risk in HCWs, whereas the probability of
having a positive PCR test in the anti-spike–seronegative HCWs
is significantly higher (1.09 per 10,000 days at risk) (Lumley et al.,
2020).
The presence of at least two consecutive negative RT-PCR
tests in respiratory samples (with samples taken at least 24 h
apart) and the appearance of specific IgG at serological test,
according to the discharge criteria of the European Centre for
Disease Prevention and Control (Yahav et al., 2021), permits to
classify the case exposed as recurrent COVID-19 with multiple
district neurological symptoms (vestibular symptoms, previously
anosmia and dysgeusia). Indeed reinfection should be considered
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FIGURE 1 | Clinical evolution of the patient: timeline.
during the first 90 days if clinical symptoms of the first episode
resolve and two PCR tests were negative before the new episode
(Yahav et al., 2021).
Currently, there are numerous reports that a number of
patients tested positive again after two consecutive negative PCR
tests or after clinical recovery (Table 1) (Falahi and Kenarkoohi,
2020). Nasopharyngeal swabs tend to have a higher sensitivity
than the other samples and are the most common method for
diagnosis of COVID-19 recurrence, regardless of the clinical
disease manifestation. With the progression of SARS-CoV-2
infection, the virus couldmigrate from the upper respiratory tract
to the lower respiratory tract and lungs, resulting in insufficient
viral load in the upper respiratory tract, which may explain the
negative result of the nasopharyngeal swab test. The detection
rate and sensitivity have been improved by multisite specimen
collection and serological assays (Table 1). The prevalence of
disease recurrence among COVID-19 recovered patients was
approximately 14.8%, ranging from 7.35 to 21.4% (Azam et al.,
2020; Hoang, 2020). The interval duration from the last negative
PCR tests to recurrent positive results ranged from 1 to 123
days (min average 16.16 ± 20.93 ds, max average 25.39 ± 23.00
ds) for 1,038 cases in a selected population of 13,565 patients
(Table 1). The case described experienced at the onset two of the
three typical symptoms in the first phase of infection, namely,
cough (68%) and shortness of breath (66%) without fever (69%).
About 92% of the patients experienced at least one of these,
less frequently in women (66, 64, 66 respectively; 90% at least
one of these; vs. men 70, 67, 71; 93%, each p < 0.001) (ISARIC
Clinical Characterisation Group, 2021). She presented symptoms
of recurrence 17 days from the last negative PCR tests, in
accordance with the literature. True reinfection has criteria that
must be considered, including isolation of the complete genome
of the virus (and not just genomic fragments) in the second
episode (Falahi and Kenarkoohi, 2020), but we did not have this
data. In our patient, we could suspect a viral reactivation due
to low level of IgG against SARS-CoV-2 detected, even without
lymphopenia. It is also possible that the immune responses
can suppress, but not completely eradicate, SARS-CoV-2, which
may have led to the false-negative results due to lower viral
loads (Chen J. et al., 2020). Once the virus starts replicating
again, the RT-PCR results reverted to positive and expressed
as a new neuroinvasion in the vestibular system. NeuroCovid
is now well-known (Whittaker et al., 2020), but recurrence of
positive RT-PCR with neurological symptoms is very rare and
no further instances of vestibular symptoms are described as
recurrence (Table 1). To our knowledge, this is the first case of
vestibular symptoms as recurrence of positive RT-PCR SARS-
CoV-2. This case shows the neuroinvasive potentials of SARS-
CoV-2 and the possibility of disease reactivation after clinical and
analytic recovery. SARS-CoV-2 might be latent in some neurons
to hide from immune surveillance (Brandt and Dieterich, 2017;
Zhang M. et al., 2020). For reasons unclear, after an apparent
remission the virus reactivated and was again identifiable in
the respiratory tract. At the same time, the multiplication in
the nervous system caused recurrence with intense neurological
disturbance, clinically highlighted by dizziness associated with
slight dyspnea.
The clinical picture and subsequent ENT are compatible
with a diagnosis of the spontaneous acute vestibular syndrome.
The most common cause is an acute peripheral vestibulopathy
known as vestibular neuritis, affecting the vestibular nerve or
“pseudoneuritis” if the acute lesions affect the root entry zone of
the eighth nerve or the vestibular nucleus (Wu Y. et al., 2020).
The neuroinvasive potential of SARS-CoV-2 is highlighted by
some studies (Baig, 2020; Magnavita et al., 2020).
A relapse of the disease with the involvement of the nervous
system may indicate that the virus can be neurotropic since the
beginning of the disease or in its recurrence form.
The virus may reach the central nervous system via the
olfactory nerve. Olfactory and gustatory dysfunctions without
rhinorrhea or nasal obstruction are distinctive of patients with
mild-to-moderate COVID-19 infection (Baig, 2020; Cooper et al.,
2020; Magnavita et al., 2020; Paniz-Mondolfi et al., 2020; Wu Y.
et al., 2020), leading to speculation regarding the olfactory nerve
as a possible route of the central nervous system entry.
Dizziness is a common onset symptom of COVID-19
(Table 2). This symptom is often considered a non-specific
neurological manifestation and is not actively researched or
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TABLE 1 | Recurrent cases reported in literature.
Reference Patients (n◦) Days from
recurrence of
COVID-19








27/138pt 11 days Nasopharyngeal and
oropharynx swabs for RT-PCR
No specified 6 pts mild symptoms,















An et al., 2020 38/242 pts 5–7 days Digestive (anal swab) and
respiratory RT-PCR tests for the




Specific total antibody IgG, IgA,
and IgM














125/1,146 pts Mean 19.9
(3–43) days





Cao et al., 2020 8/108 pts 6–28 days Deep nasal cavity swab










20–30 days Nasopharyngeal swabs RT-PCR
Cts-values ≥ 24
No specified No clinical symptoms
Chae et al., 2020 1pt 6 days Naso- and oropharyngeal swab
RT-PCR
No specified Ground-glass
opacities in the right
upper lobe








No specified Respiratory symptoms
had already improved
Chen J. et al.,
2020
81/1,067 pts 7–10 days Throat-swabs RT-PCR tests No specified 84.0% (68) mild,
14.8% (12) severe,





Chen M. et al.,
2020
6/11 pts 6–27 days Oropharyngeal swab RT-PCR No specified Mild to moderate
Chen S. L. et al.,
2020
189/1,282 pts 28 days Nasopharyngeal and anal
swabs specimens RT-PCR










Chen Y. et al.,
2020
4 pts 3 days after
discharge
Nasopharyngeal,










50 days Nasopharyngeal swabs for the
RT-PCR test






Frontiers in Human Neuroscience | www.frontiersin.org 4 August 2021 | Volume 15 | Article 666468
Zaffina et al. Occupational Case of NeuroCovid-19 Recurrence
TABLE 1 | Continued
Reference Patients (n◦) Days from
recurrence of
COVID-19












Nasal and pharyngeal swab
specimens, stool and sputum
specimens RT-PCR





Dou C. et al.,
2020
1pt 15 days Oropharyngeal swab RT-PCR No specified Asymptomatic
Dou P. et al.,
2020
2 pts 17 days Throat and anus swab RT-PCR No specified Asymptomatic
Du et al., 2020 3/126 pts 10–18 days Nasopharynx and oropharynx
swab RT-PCR targeting the









1pt 10 days Nasopharyngeal swabs for the
RT-PCR test
No specified Critical
Fu et al., 2020 3 1–5 days Nasopharyngeal swab RT-PCR;
IgM and IgG antibodies
No specified Asymptomatic
Gao et al., 2020 70-year-old
male patient
15 days Nasopharyngeal, blood, and
rectal swab RT-PCR
ORF1ab and N genes







Sputum specimen RT-PCR for
ORF1ab and the N gene
No specified No clinical symptoms
Gidari et al.,
2021
9 pts 14–50 days Respiratory samples RT-PCR





















No specified Median duration of
symptoms was 18
days for the first
episode and 10 days
for the second one

















9/13 pts 15–48 days Nasopharyngeal swabs RT-PCR







Hao et al., 2020 24/104 pts Quarantine Respiratory specimens
(nasal/throat swab or sputum)
RT-PCR tests of
No specified No clinical symptoms
He et al., 2020 1pt 8 days Throat swab samples RT-PCR No specified Dry cough, arthralgia Headache
Hu R. et al.,
2020
11/69 pts 14 days (range,
9–17 days).
Nasopharyngeal swabs RT-PCR No specified No clinical symptoms
Huang et al.,
2020
69/414 pts Median 19 days,
range 6–52 days
Nasopharyngeal and anal
















Frontiers in Human Neuroscience | www.frontiersin.org 5 August 2021 | Volume 15 | Article 666468
Zaffina et al. Occupational Case of NeuroCovid-19 Recurrence
TABLE 1 | Continued
Reference Patients (n◦) Days from
recurrence of
COVID-19








6/35 pts 9–10 days Throat swabs or sputum
samples for RT-PCR
No specified 1 expectoration,










6/29 pts 13–24 days Nasopharyngeal swabs RT-PCR No specified Asymptomatic or mild




Li C. et al., 2020 15/85 pts 9–30 days Nasopharyngeal swabs RT-PCR No specified Two patients (13.3%)
had cough, one
(6.6%) had dyspnea
Li J. et al., 2020 50-year-old
man
Days 34 and 38
during
quarantine
Nasopharyngeal swabs RT-PCR No specified No clinical symptoms
Li Y. et al., 2020 6/13 pts 6–14 days Respiratory swabs qRT-PCR for





Ling et al., 2020 11/66 6–11 days Oropharyngeal swab, stool,








Liu B. et al.,
2020
8/47 pts From 8 to 39
days after viral
shedding
Anal and throat swab samples
RT-PCR




(HR1–HR2) in the S2 domain;
and the N, membrane (M), and
E proteins.



























Liu J. et al., 2020 15/62 pts 14 days Respiratory tract samples
RT-PCR spike receptor-binding
domain (S-RBD) and N spike
protein as antigens.
ORF1ab, NP genes fragments,
Ct ≤ 38








Liu T. et al., 2020 11/150 pts 38 days, range
35–44 days
Throat swabs RT-PCR and










30 days after 2
negative tests
Nasopharyngeal swab RT-PCR
2 targeting E-gene, RdRP-gene
and N-gene
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TABLE 1 | Continued
Reference Patients (n◦) Days from
recurrence of
COVID-19




Clinical symptoms Recurrence with
neurological signs
Lu et al., 2020 87/619 pts 2–19 days Nasopharyngeal swabs, throat
swabs and anal swabs RT-PCR
and multiplex PCR sequencing





































Mei et al., 2020 23/651 pts 4–38 days Nasopharyngeal and
oropharyngeal swabs qRT-PCR
immunochromatographic strip
assay for anti-SARS-CoV-2 viral
immunoglobulins








Throat or anal swab on
qRT-PCR
No specified Milder symptoms
Qiao et al., 2020 1/15 pts 16 days Throat swabs RT-PCR No specified Mild (itchy throat)
Ravioli et al.,
2020
2 pts 14–21 days Nasopharyngeal swab RT-PCR No specified Moderate (1, 50.0%)





120 days Nasopharyngeal swabs RT-PCR No specified Acute Respiratory
Distress Syndrome
Sen et al., 2020 5 pts 5–43 days Nasopharyngeal swabs RT-PCR No specified 1 pt asymptomatic/ 4





48 days Nasopharyngeal swabs RT-PCR
RdRp gene and E gene.
Ct ≤ 30

















No specified Symptomatic second
episode
2 pts anosmia
















Wang H. et al.,
2020
1pt 15 days Sputum, nasopharyngeal
swabs RT-PCR
No specified Mild
Wang X. et al.,
2020
8/131 pts 7–30 days Nose and throat RT-PCR
ORF1b and N




21/106 pts 13–16 days Nasopharyngeal swab RT-PCR





1 a mild cough, 20
asymptomatic
(Continued)
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TABLE 1 | Continued
Reference Patients (n◦) Days from
recurrence of
COVID-19




Clinical symptoms Recurrence with
neurological signs
Wu F. et al.,
2020
1pt 6 days Throat swab RT-PCR No specified Mild
Wu J. et al.,
2020
10/60 pts In-home 2-week
quarantine
Nasopharyngeal and anal swab
samples RT-PCR
No specified 2 occasionally cought,
8 no clinical symptoms






Throat swab samples or deep














Xie et al., 2020 22/161 pts 1–14 days Throat swabs and anal swabs
RT-PCR
No specified No data
Xing et al., 2020 2/62 pts 6–14 days Throat swab samples RT-PCR






Yang et al., 2020 93/479 pts 7-90 days RT-qPCR
Ct ≤ 40











Ye et al., 2020 5/55 pts 30 days Throat swab samples qRT-PCR No specified Fever
Yoo et al., 2020 1pt 14 days Upper airway (nasopharyngeal
swab), lower airway (sputum),
urine, stool, saliva, and serum.
qRT-PCR










































Zhang B. et al.,
2020
7 pts 7–11 days Throat or rectal swabs RT-PCR No specified Asymptomatic
Zhang J.-F.
et al., 2020
1pt 4 days Throat swab sample RT-PCR No specified Asymptomatic
Zhang R. Z.
et al., 2020
4 pts 14–21 days Nasopharyngeal swab RT-PCR No specified Asymptomatic












7 days Salivary tests RT-PCR and fecal
nucleic acid (RNA) test
No specified No symptoms




5 days after Sputum or nasopharyngeal
swab specimens RT-PCR
ORF 1a/1b and nuclear gene
Ct-values ≤ 40
No specified Higher density of
consolidation on chest
CT
Zhou X. et al.,
2020
17/98 pts 3–8.5 days Oropharyngeal swab RT-PCR.
Total exon sequencing
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TABLE 1 | Continued
Reference Patients (n◦) Days from
recurrence of
COVID-19




Clinical symptoms Recurrence with
neurological signs




Throat swabs RT-PCR No specified Two patients
developed clinical
symptoms: one of the
patients developed a
cough, while the other
patient had diarrhea
RT-PCR, reverse transcriptase polymerase chain reaction; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction; Ct, cycle threshold; ORF1ab, open reading frame1ab;
N, nucleocapsid gene; E, envelope gene; RdRP, RNA-dependent RNA polymerase genes.
TABLE 2 | Dizziness as clinical onset symptom reported in literature.
References Study Dizziness % Hearing or Vestibular impairment
Chen T. et al., 2020 Retrospective study Dizziness 7.66%
Chern et al., 2021 Case report Bilateral sudden sensorineural hearing loss, bilateral aural
fullness, and vertigo
Chirakkal et al., 2020 Case report Hearing loss and tinnitus
Correia et al., 2020 Systematic review Dizziness 13.9 %
Degen et al., 2020 Case report Asymmetric and bilateral sudden hearing loss and tinnitus
Di Carlo et al., 2020 Systematic review Dizziness 13.9 %
Fadakar et al., 2020 Case report Progressive vertigo in cerebellitis
Fidan, 2020 Case report Acute otitis media, hearing loss, and tinnitus
Hu Z. et al., 2020 Retrospective study Dizziness 4%
Iltaf et al., 2020 Cross-sectional study Vertigo 3.4%
Sia, 2020 Case Report Dizziness
Karadaş et al., 2020 Prospective clinical study Dizziness 6.7%
Karimi-Galougahi et al., 2020 Case series 6 pts with acute-onset hearing loss and/or vertigo
Kilic et al., 2020 Case report Sudden hearing loss
Klironomos et al., 2020 Retrospective study (one
case)
Vestibular neuronitis
Lamounier et al., 2020 Case report Sudden hearing loss
Liu et al., 2020b Case report Vertigo
Lon et al., 2020 Cross-sectional Dizziness 20%
Maharaj and Hari, 2020 Case report Vertigo and tinnitus
Maharaj et al., 2020 Systematic review 100% hearing loss, 10% associated vestibular symptoms
Malayala and Raza, 2020 Case report Acute vestibular neuritis
Mao et al., 2020 Retrospective study Dizziness 16.8%
Mi et al., 2020 Retrospective study Dizziness 33%
Özçelik Korkmaz et al., 2020 Case series Dizziness 31.8% Tinnitus (11%), true vertigo (6%), hearing impairment (5.1%)
Qin et al., 2020 Case series Dizziness 8.1%
Romero-Sánchez et al., 2020 Retrospective study Dizziness 6.1%
Shahriarirad et al., 2020 Case series Dizziness/vertigo 39.8%
Sriwijitalai and Wiwanitkit, 2020 Case series Six cases of patients with sudden hearing loss
Sun et al., 2020 Case report Bilateral hearing loss and tinnitus
Viola et al., 2020 Multicentric study Dizziness 94.1% Thirty-four patients (18.4%) reported equilibrium disorders after
COVID-19 diagnosis. Of these, 32 patients reported dizziness
(94.1%) and 2 (5.9%) reported acute vertigo attacks.
Forty-three patients (23.2%) reported tinnitus; 14 (7.6%)
reported both tinnitus and equilibrium disorders.
Wang D. et al., 2020 Case series Dizziness 6.5%
Zhong et al., 2020 Retrospective study Dizziness 10.4%
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detailed in the description of the clinical picture. This can
lead to variability of prevalence estimates, ranging from 3 to
16% between studies. Dizziness such as headache, fatigue, and
myalgia are all likely to be caused by the systemic condition if
not well-characterized. Specific vestibular or hearing impairment
is rarely reported (Table 2). Vertigo should be investigated in
SARS-CoV-2 patients and considered along with neurological
signs induced by the invasion of the vestibular pathway from
the nerve to the vestibular nuclei complex. It is plausible
to hypothesize that if the SARS-CoV-2 can also reach the
brain from the lungs through the vagus nerve, the virus will
invade the brainstem starting with the vagal nucleus and
surrounding sites, including the respiratory control center and
more, which can lead to more respiratory dysfunction that
further exacerbates the damage caused by the primary infection
in the lungs or others neurological symptoms (Lukiw et al.,
2020; Yachou et al., 2020), such as vestibular impairment. This
hypothesis is supported by the evidence of the presence of a
consistent angiotensin-converting enzyme (ACE2) expression
across the cerebral cortex. The highest ACE2 expression was
found in the pons and the medulla oblongata (Guan et al.,
2020). Indeed, SARS-CoV-2 appears to bind exclusively to the
ACE2 protein, a single-pass type 1 transmembrane receptor
with its enzymatically active domain exposed on the surface
of multiple cell types, such as type II alveolar cells of the
respiratory system, enterocytes and intestinal epithelial cells,
endothelial cells, epithelial cells of the conjunctival epithelium,
kidney cells (renal tubules), and certain immune cells, such
as the alveolar monocytes/macrophages and certain cells of
the CNS including those of the cerebral cortex, especially the
brainstem (Zubair et al., 2019; Chigr et al., 2020; Kabbani
and Olds, 2020; Li C. et al., 2020; Li M. et al., 2020;
Panupattanapong and Brooks, 2020; Zhou L. et al., 2020;
154). The highest levels of ACE2-expression in the brain
were found in the pons and medulla oblongata, the breathing
centers of the brain, which may in part explain the unusually
strong ability of SARS-CoV-2 to disrupt normal respiration
and pulmonary manifestations including shortness of breath,
impaired breathing, and severe respiratory distress. Significant
neuroinvasion involving SARS-CoV-2 has been reported from
both patients and experimental animals, where the brainstem
was heavily infected from apparent spreading via a synapse-
connected route to the medullary cardiorespiratory centers
(Panupattanapong and Brooks, 2020).
A limitation of this case consists of the absence of
magnetic resonance documentation of vestibular impairment
and the genetic characterization of the viruses at the onset
and recurrence of COVID-19. The rapid resolution of clinical
symptoms within a few days and the trend of not submitting
the non-hospitalized patient to neuroimaging exam above all
in patients with low suspicions of CNS disease and plan
for outpatient ENT visit in the pandemic period, prompted
the emergency physician not to proceed. Several causes for
repositive tests for SARS-CoV-2 in COVID-19 patients during
the recovery period have been described. They include false
RT-PCR results or positive due to traces of the RNA genome,
intermittent virus shedding, viral reactivation in people with low
antibody levels or immunity, reinfection with another SARS-
CoV-2 strain, an acute severe systemic inflammatory response
known as cytokine release syndrome (CRS), or exposure to a
contaminated environmental surface after discharge (Yang et al.,
2020; Dao et al., 2021). Various molecular diagnostic assays
have been developed and used worldwide, but the differences
in their diagnostic performances remain poorly understood
(Matsumura et al., 2020; Liotti et al., 2021; Wang M. et al.,
2021). Most of the articles do not report the commercial
kit used for RT-PCR, and, where reported, the sensitivity
and specificity data for the kit is not often available in the
literature (Table 1). All the assays exhibited a specificity of
100%, while sensitivity varied (Table 1). The RT-PCR test cannot
distinguish between live and dead viruses, but most recurrence
of positive RT-PCR is expressed in an asymptomatic way;
therefore likely due to dead viruses. We did not perform a
genetic characterization of the viruses in order to distinguish
between reinfection and reactivation of SARS-CoV-2 in our
repositive patient.
CONCLUSIONS
This case is suggestive of colonization of the nervous system that
can also result in clinical manifestations in cases of recurrence
witnessing the diffusion or permanence of SARS-CoV-2 in the
nervous system. It also suggests the neurotrophic hypothesis
with the possibility of brainstem invasion (pons and medulla
oblongata) and the possibility of recurrence with a SARS-CoV-
2 positive RT-PCR test and of clinical recurrence with specific
neurological symptoms.
Neurological symptoms should be sought and typified in each
SARS-CoV-2 patient.
With the outbreak of COVID-19, to better manage the current
phase of the pandemic, we should be vigilant for the presence of
any neurological symptoms, both as an onset and as a recurrence
of infection.
On the basis of the literature examined and reviewed, for
recurrence cases and vestibular symptoms during COVID-
19, to our knowledge, this is the first case of recurrence
with vestibular impairment as neurological symptom, and we
suspect it is likely due to viral reactivation. The PCR retest
positivity cannot differentiate between reinfectivity and relapse,
and dead-viral RNA detection, serological antibody testing,
and viral genome sequencing could be always performed in
recurrence cases.
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Karadaş, Ö., and Öztürk, B., Sonkaya, A. R. (2020). A prospective clinical study of
detailed neurological manifestations in patients with COVID-19. Neurol. Sci.
41, 1991–1995. doi: 10.1007/s10072-020-04547-7
Karimi-Galougahi, M., Naeini, A. S., Raad, N., Mikaniki, N., and Ghorbani,
J. (2020). Vertigo and hearing loss during the COVID-19 pandemic
- is there an association? Acta Otorhinolaryngol. Ital. 40, 463–465.
doi: 10.14639/0392-100X-N0820
KCDA. (2020). Findings From Investigation and Analysis of Re-Positive
Cases. Available online at: https://www.cdc.go.kr/board/board.es?mid=
a30402000000andbid=0030. (accessed September 7, 2020).
Kilic, O., Kalcioglu, M. T., Cag, Y., et al. (2020). Could sudden sensorineural
hearing loss be the sole manifestation of COVID-19? An investigation into
SARS-COV-2 in the etiology of sudden sensorineural hearing loss. Int. J. Infect.
Dis. 97, 208–211 doi: 10.1016/j.ijid.2020.06.023
Klironomos, S., Tzortzakakis, A., Kits, A., Öhberg, C., Kollia, E., Ahoromazdae,
A., et al. (2020). Nervous system involvement in coronavirus disease 2019:
results from a retrospective consecutive neuroimaging cohort. Radiology 297,
E324–E334. doi: 10.1148/radiol.2020202791
Lamounier, P., Franco Gonçalves, V., Ramos, H. V. L., Gobbo, D. A., Teixeira, R.
P., Dos Reis, P. C., et al. (2020). A 67-year-old woman with sudden hearing
loss associated with SARS-CoV-2 infection. Am. J. Case Rep. 21:e927519.
doi: 10.12659/AJCR.927519
Lan, L., Xu, D., Ye, G., Xia, C., Wang, S., Li, Y., et al. (2020). Positive RT-PCR
test results in patients recovered from COVID-19. JAMA 323, 1502–1503.
doi: 10.1001/jama.2020.2783
Landi, F., Gremese, E., Rota, E., Carfi, A., Benvenuto, F., Ciciarello, F., et al.
(2020). Positive RT-PCR nasopharyngeal swab in patients recovered from
COVID-19 disease: when does quarantine really end? J. Infect. 81, e1–e3.
doi: 10.1016/j.jinf.2020.08.034
Leonardi, M., Padovani, A., and McArthur, J. C. (2020). Neurological
manifestations associated with COVID-19: a review and a call for action. J.
Neurol. 267, 1573–1576. doi: 10.1007/s00415-020-09896-z
Li, C., Luo, F., Xie, L., Gao, Y., Zhang, N., and Wu, B. (2020). Chest CT
study of fifteen COVID-19 patients with positive RT-PCR retest results after
discharge. Quant. Imaging Med. Surg. 10, 1318–1324. doi: 10.21037/qims-
20-530
Li, J., Long, X., Fang, X., Zhang, Q., Hu, S., Lin, Z., et al. (2020). SARS-CoV-2
positivity in a discharged COVID-19 patient: a case report. Clin. Microbiol.
Infect. 26, 1115–1117. doi: 10.1016/j.cmi.2020.04.032
Frontiers in Human Neuroscience | www.frontiersin.org 12 August 2021 | Volume 15 | Article 666468
Zaffina et al. Occupational Case of NeuroCovid-19 Recurrence
Li, M. Y., Li, L., Zhang, Y., and Wang, X. S. (2020). Expression of the SARSCoV-2
cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty
9:45. doi: 10.1186/s40249-020-00662-x
Li, Y., Hu, Y., Yu, Y., Zhang, X., Li, B., Wu, J., et al. (2020). Positive result of Sars-
Cov-2 in faeces and sputum from discharged patients with COVID-19 in Yiwu,
China. J. Med. Virol. 92, 1938–1947. doi: 10.1002/jmv.25905
Li, Y. C., Bai, W. Z., and Hashikawa, T. (2020). The neuroinvasive potential of
SARSCoV2 may be at least partially responsible for the respiratory failure of
COVID-19 patients. J. Med. Virol. 92, 552–555. doi: 10.1002/jmv.25824
Ling, Y., Xu, S. B., Lin, Y. X., Tian, D., Zhu, Z. Q., Dai, F. H., et al.
(2020). Persistence and clearance of viral RNA in 2019 novel coronavirus
disease rehabilitation patients. Chin. Med. J. (Engl.). 133, 1039–1043.
doi: 10.1097/CM9.0000000000000774
Liotti, F. M., Menchinelli, G., Marchetti, S., Morandotti, G. A., Sanguinetti, M.,
Posteraro, B., et al. (2021). Evaluation of three commercial assays for SARS-
CoV-2 molecular detection in upper respiratory tract samples. Eur. J. Clin.
Microbiol. Infect. Dis. 40, 269–277. doi: 10.1007/s10096-020-04025-0
Liu, B., Shi, Y., Zhang, W., Li, R., He, Z., Yang, X., et al. (2020).
Recovered COVID-19 patients with recurrent viral RNA exhibit lower
levels of anti-RBD antibodies. Cell. Mol. Immunol. 17, 1098–1100.
doi: 10.1038/s41423-020-00528-0
Liu, C., Ye, L., Xia, R., Zheng, X., Yuan, C., Wang, Z., et al. (2020a).
Chest CT and clinical follow-up of discharged patients with COVID-19
in Wenzhou City, Zhejiang, China. Ann. Am. Thorac. Soc. 17, 1231–1237.
doi: 10.1513/AnnalsATS.202004-324OC
Liu, C., Zhou, J., Xia, L., Cheng, X., and Lu, D. (2020b). 18F-FDG PET/CT
and serial chest CT findings in a COVID-19 patient with dynamic
clinical characteristics in different period. Clin. Nucl. Med. 45, 495–496.
doi: 10.1097/RLU.0000000000003068
Liu, F., Cai, Z. B., Huang, J. S., Yu, W. Y., Niu, H. Y., Zhang, Y., et al. (2020).
Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-
19: dynamic results from 108 days of follow-up. Pathog Dis. 78:ftaa031.
doi: 10.1093/femspd/ftaa031
Liu, J., Lian, R., Zhang, G., Hou, B., Wang, C., Dong, J., et al. (2020). Changes
in serum virus-specific IgM/IgG antibody in asymptomatic and discharged
patients with reoccurring positive COVID-19 nucleic acid test (RPNAT). Ann.
Med. 53, 34–42. doi: 10.1080/07853890.2020.1811887
Liu, T., Wu, S., Zeng, G., Zhou, F., Li, Y., Guo, F., et al. (2020). Recurrent
positive SARS-CoV-2: immune certificate may not be valid. J. Med. Virol.
29:10.1002/jmv.26074. doi: 10.1002/jmv.26074
Loconsole, D., Passerini, F., Palmieri, V. O., Centrone, F., Sallustio, A., Pugliese, S.,
et al. (2020). Recurrence of COVID-19 after recovery: a case report from Italy.
Infection 16, 1–3. doi: 10.1007/s15010-020-01444-1
Lon, I. L., Lio, C. F., Cheong, H. H., Lei, C. I., Cheong, T. H., Zhong, X., et al.
(2020). Evolution of SARS-CoV-2 RNA shedding in clinical specimens and
clinical characteristics of 10 patients with COVID-19 in Macau. Int. J. Biol. Sci.
16, 1698–1707. doi: 10.7150/ijbs.45357
Lu, J., Peng, J., Xiong, Q., Liu, Z., Lin, H., Tan, X., et al. (2020). Clinical,
immunological and virological characterization of COVID-19 pa- tients
that test re-positive for SARS-CoV-2 by RT-PCR. EBio Med. 59:102960.
doi: 10.1016/j.ebiom.2020.102960
Luciani, M., Bentivegna, E., Spuntarelli, V., Lamberti, P. A., Cacioli, G., Del
Porto, F., et al. (2020). Recurrent COVID-19 pneumonia in the course of
chemotherapy: consequence of a weakened immune system? J. Med. Virol.
28:10.1002/jmv.26701. doi: 10.1002/jmv.26701
Lukiw, W. J., Pogue, A., and Hill, J. M. (2020). SARS-CoV-2 infectivity
and neurological targets in the brain. Cell Mol. Neurobiol. 2020, 1–8.
doi: 10.1007/s10571-020-00947-7
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth,
A., Hatch, S. B., et al. (2020). Antibody status and incidence of SARS-
CoV-2 infection in health care workers. N. Engl. J. Med. 384, 533–540.
doi: 10.1056/NEJMoa2034545
Magnavita, N., Tripepi, G., and Di Prinzio, R. R. (2020). Symptoms in health
care workers during the COVID-19 epidemic. a cross-sectional survey. Int. J.
Environ. Res. Public Health. 17:5218. doi: 10.3390/ijerph17145218
Maharaj, S., Bello Alvarez, M., Mungul, S., and Hari, K. (2020). Otologic
dysfunction in patients with COVID-19: a systematic review. Laryngos. Investig.
Otolaryngol. 5, 1192–1196. doi: 10.1002/lio2.498
Maharaj, S., and Hari, K. (2020). Congenital inner ear abnormalities and
COVID-19-related ear infections. Ear Nose Throat J. 23:145561320968934.
doi: 10.1177/0145561320968934
Malayala, S. V., and Raza, A. (2020). A case of COVID-19-induced vestibular
neuritis. Cureus 12:e8918. doi: 10.7759/cureus.8918
Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., et al. (2020).
Neurological manifestations of hospitalized patients with COVID-19 in
Wuhan, China: a retrospective case series study.medRxiv 2020.02.22.20026500.
doi: 10.1101/2020.02.22.20026500
Mardani, M., Nadji, S. A., Sarhangipor, K. A., Sharifi-Razavi, A., and
Baziboroun, M. (2020). COVID-19 infection recurrence presenting
with meningoencephalitis. New Microbes New Infect. 37:100732.
doi: 10.1016/j.nmni.2020.100732
Matsumura, Y., Shimizu, T., Noguchi, T., Nakano, S., Yamamoto, M., and Nagao,
M. (2020). Comparison of 12 molecular detection assays for SARS-CoV-2.
bioRxiv 2020: 06.24.170332. doi: 10.1101/2020.06.24.170332
Mei, Q., Li, J., Du, R., Yuan, X., Li, M., and Li, J. (2020). Assessment of patients
who tested positive for COVID-19 after recovery. Lancet Infect. Dis. 20, P1004–
P1005. doi: 10.1016/S1473-3099(20)30433-3
Mi, B., Chen, L., Xiong, Y., Xue, H., Zhou, W., Liu, G., et al. (2020). Characteristics
and early prognosis of COVID-19 infection in fracture patients. J. Bone Joint
Surg. 102, 750–758. doi: 10.2106/JBJS.20.00390
Nepal, G., Rehrig, J. H., Shrestha, G. S., Shing, Y. K., Yadav, J. K., Ojha, R., et al.
(2020). Neurological manifestations of COVID-19: a systematic review. Crit.
Care. 24:421. doi: 10.1186/s13054-020-03121-z
Özçelik Korkmaz, M., Egilmez, O. K., and Özçelik, M. A., Güven, M.
(2020). Otolaryngological manifestations of hospitalised patients with
confirmed COVID-19 infection. Eur. Arch. Otorhinolaryngol. 3, 1–11.
doi: 10.1007/s00405-020-06396-8
Paniz-Mondolfi, C., Bryce, Z., Grimes, R. E., Gordon, J., Reidy, J., Lednicky,
E., et al. (2020). Central nervous system involvement by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). J. Med. Virol. 92, 699–702.
doi: 10.1002/jmv.25915
Panupattanapong, S., and Brooks, E. B. (2020). New spectrum of COVID-19
manifestations in children: Kawasaki-like syndrome and hyperinflammatory
response. Cleve Clin. J. Med. 1–7 doi: 10.3949/ccjm.87a.ccc039
Peng, J., Wang, M., Zhang, G., and Lu, E. (2020). Seven discharged patients turning
positive again for SARS-CoV-2 on quantitative RT-PCR. Am. J. Infect. Control.
48, 725–726. doi: 10.1016/j.ajic.2020.03.017
Qiao, X.-M., Xu, X.-F., Zi, H., Liu, G.-X., Li, B.-H., Du, X., et al. (2020). Re- positive
cases of nucleic acid tests in discharged patients with COVID-19: a follow-up
study. Front. Med. 7:349. doi: 10.3389/fmed.2020.00349
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., et al. (2020). Dysregulation
of immune response in patients with coronavirus 2019 (COVID-19) inWuhan,
China. Clin. Infect. Dis. 71, 762–768. doi: 10.1093/cid/ciaa248
Ravioli, S., Ochsner, H., and Lindner, G. (2020). Reactivation of COVID-
19 pneumonia: a report of two cases. J. Inf. Secur. 81, e72–e73.
doi: 10.1016/j.jinf.2020.05.008
Romero-Sánchez, C. M., Díaz-Maroto, I., Fernández-Díaz, E., Sánchez-Larsen, Á.,
Layos-Romero, A., García-García, J., et al. (2020). Neurologic manifestations in
hospitalized patients with COVID-19: the ALBACOVID registry.Neurology 95,
e1060–e1070. doi: 10.1212/WNL.0000000000009937
Salcin, S., and Fontem, F. (2020). Recurrent Sars-Cov-2 infection resulting in acute
respiratory distress syndrome and development of pulmonary hypertension:
a case report. Respir. Med. Case Rep. 5:101314. doi: 10.1016/j.rmcr.2020.
101314
Sen, M. K., Gupta, N., Yadav, S. R., Kumar, R., Singh, B., and Ish, P.
(2020). Contentious issue in recurrent COVID-19 infection: reactivation or
reinfection. Turk Thorac. J. 21, 463–466. doi: 10.5152/TurkThoracJ.2020.
20164
Shahriarirad, R., Khodamoradi, Z., Erfani, A., Hosseinpour, H., Ranjbar, K.,
Emami, Y., et al. (2020). Epidemiological and clinical features of 2019 novel
coronavirus diseases (COVID-19) in the South of Iran. BMC Infect. Dis. 20:427.
doi: 10.1186/s12879-020-05128-x
Sharma, R., Sardar, S., Mohammad Arshad, A., Ata, F., Zara, S., and Munir, W.
(2020). A patient with asymptomatic SARS-CoV-2 infection who presented
86 days later with COVID-19 pneumonia possibly due to reinfection with
SARS-CoV-2. Am. J. Case Rep. 21:e927154. doi: 10.12659/AJCR.927154
Frontiers in Human Neuroscience | www.frontiersin.org 13 August 2021 | Volume 15 | Article 666468
Zaffina et al. Occupational Case of NeuroCovid-19 Recurrence
Sia, J. (2020). Dizziness can be an early sole clinical manifestation for
COVID-19 infection: a case report. J. Am. Coll. Emerg. Physicians Open.
23:10.1002/emp2.12185. doi: 10.1002/emp2.12185
Sriwijitalai, W., and Wiwanitkit, V. (2020). Hearing loss and COVID-19: a note.
Am. J. Otolaryngol. 41:102473. doi: 10.1016/j.amjoto.2020.102473
Sun, R., Liu, H., and Wang, X. (2020). Mediastinal emphysema, giant bulla, and
pneumothorax developed during the course of COVID-19 pneumonia. Korean
J. Radiol. 21, 541–544. doi: 10.3348/kjr.2020.0180
Tian, M., Long, Y., Hong, Y., Zhang, X., and Zha, Y. (2020). The
treatment and follow-up of ’recurrence’ with discharged COVID-19
patients: data from Guizhou, China. Environ. Microbiol. 22, 3588–3592.
doi: 10.1111/1462-2920.15156
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A.
R., et al. (2020). COVID-19 re-infection by a phylogenetically distinct SARS-
coronavirus-2 strain confirmed by whole genome sequencing. Clin. Infect. Dis.
2020:ciaa1275. doi: 10.1093/cid/ciaa1275
Vavougios, G. D. (2020). SARS-CoV-2 dysregulation of PTBP1 and YWHAE/Z
gene expression: a primer of neurodegeneration.Med. Hypotheses. 144:110212.
doi: 10.1016/j.mehy.2020.110212
Viola, P., Ralli, M., Pisani, D., Malanga, D., Sculco, D., Messina, L., et al. (2020).
Tinnitus and equilibrium disorders in COVID-19 patients: preliminary results.
Eur. Arch. Otorhinolaryngol. 23, 1–6. doi: 10.1007/s00405-020-06440-7
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical
characteristics of 138 hospitalized patients with 2019 novel coronavirus –
infected pneumonia in Wuhan – China. J. Am. Med. Assoc. 323, 1061–1069.
doi: 10.1001/jama.2020.1585
Wang, H., Li, Y., Wang, F., Du, H., and Lu, X. (2020). Rehospitalization of a
recovered coronavirus disease 19 (COVID-19) child with positive nucleic acid
detection. Pediatr. Infect. Dis. J. 39:e69. doi: 10.1097/INF.0000000000002690
Wang, M., Chen, D., Wu, W., Tang, H., Kan, L., Zong, Z., et al. (2021).
Analytical performance evaluation of five RT-PCR kits for severe acute
respiratory syndrome coronavirus 2. J. Clin. Lab. Anal. 2021:e23643.
doi: 10.1002/jcla.23643
Wang, X., Xu, H., Jiang, H., Wang, L., Lu, C., Wei, X., et al. (2020). Clinical features
and outcomes of discharged coronavirus disease 2019 patients: a prospective
cohort study. QJM. 113, 657–665. doi: 10.1093/qjmed/hcaa178
Whittaker, A., Anson, M., and Harky, A. (2020). Neurological manifestations of
COVID-19: a systematic review and current update. Acta Neurol. Scand. 142,
14–22. doi: 10.1111/ane.13266
Wong, J., Koh, W. C., Momin, R. N., Alikhan, M. F., Fadillah, N., and Naing,
L. (2020). Probable causes and risk factors for positive SARS-CoV-2 test
in recovered patients: evidence from Brunei Darussalam. J. Med. Virol. 92,
2847–2851. doi: 10.1002/jmv.26199
Wu, F., Zhang, W., Zhang, L., Wang, D., and Wan, Y. (2020). Discontinuation
of antiviral drugs may be the reason for recovered COVID-19 patients testing
positive again. Br. J. Hosp. Med. 81, 1–2. doi: 10.12968/hmed.2020.0156
Wu, J., Liu, X., Liu, J., Liao, H., Long, S., Zhou, N., et al. (2020).
Coronavirus disease 2019 test results after clinical recovery and hospital
discharge among patients in China. JAMA Netw. Open. 3:e209759.
doi: 10.1001/jamanetworkopen.2020.9759
Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., et al. (2020). Nervous
system involvement after infection with COVID-19 and other coronaviruses.
Brain Behav. Immun. 87, 18–22. doi: 10.1016/j.bbi.2020.03.031
Xiao, A. T., Tong, Y. X., and Zhang, S. (2020). False negative of RT-PCR and
prolonged nucleic acid conversion in COVID-19: rather than recurrence. J.
Med. Virol. 9:10.1002/jmv.25855. doi: 10.1002/jmv.25855
Xiao, Y., Shi, X., She, Q., Chen, Q., Pan, H., Zhang, J., et al. (2020).
Exploration of turn-positive RT-PCR results and factors related to treatment
outcome in COVID-19: a retrospective cohort study. Virulence 11, 1250–1256.
doi: 10.1080/21505594.2020.1816076
Xie, C., Lu, J., Wu, D., Zhang, L., Zhao, H., Rao, B., et al. (2020). False negative rate
of COVID-19 is eliminated by using nasal swab test. Travel Med. Infect. Dis.
37:101668. doi: 10.1016/j.tmaid.2020.101668
Xing, Y., Mo, P., Xiao, Y., Zhao, O., Zhang, Y., andWang, F. (2020). Post-discharge
surveillance and positive virus detection in two medical staff recovered from
coronavirus disease 2019 (COVID-19), China, January to February 2020. Euro
Surveill. 25:2000191. doi: 10.2807/1560-7917.ES.2020.25.10.2000191
Xiong, W., Mu, J., Guo, J., Lu, L., Liu, D., Luo, J., et al. (2020). New onset
neurologic events in people with COVID-19 in 3 regions in China. Neurology
95, e1479–e1487. doi: 10.1212/WNL.0000000000010034
Yachou, Y., El Idrissi, A., Belapasov, V., and Ait Benali, S. (2020). Neuroinvasion,
neurotropic, and neuroinflammatory events of SARS-CoV-2, understanding
the neurological manifestations in COVID-19 patients. Neurol. Sci. 41,
2657–2669. doi: 10.1007/s10072-020-04575-3
Yahav, D., Yelin, D., Eckerle, I., et al. (2021). Definitions for coronavirus disease
2019 reinfection, relapse and PCR re-positivity. Clin. Microbiol. Infect. 27,
315–318. doi: 10.1016/j.cmi.2020.11.028
Yang, C., Jiang, M., Wang, X., Tang, X., Fang, S., Li, H., et al. (2020). Viral
RNA level, serum antibody responses, and transmission risk in recovered
COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results:
a population-based observational cohort study. Emerg. Microbes Infect. 9,
2368–2378. doi: 10.1080/22221751.2020.1837018
Ye, G., Pan, Z., Pan, Y., Deng, Q., Chen, L., Li, J., et al. (2020). Clinical
characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.
J. Infect. 80, e14–e17. doi: 10.1016/j.jinf.2020.03.001
Yoo, S. Y., Lee, Y., Lee, G. H., and Kim, D. H. (2020). Reactivation of SARSCoV-2
after recovery. Pediatr. Int. 62, 879–881. doi: 10.1111/ped.14312
Yuan, B., Liu, H. Q., Yang, Z. R., Chen, Y. X., Liu, Z. Y., Zhang, K.,
et al. (2020). Recurrence of positive SARS-CoV-2 viral RNA in recovered
COVID-19 patients during medical isolation observation. Sci. Rep. 10:11887.
doi: 10.1038/s41598-020-68782-w
Yuan, J., Kou, S., Liang, Y., Zeng, J., Pan, Y., and Liu, L. (2020). PCR assays
turned positive in 25 discharged COVID-19 patients.Clin. Infect. Dis. 8:ciaa398.
doi: 10.1093/cid/ciaa398
Zhang, B., Liu, S., Dong, Y., Zhang, L., Zhong, Q., Zou, Y., et al. (2020).
Positive rectal swabs in young patients recovered from coronavirus disease 2019
(COVID-19). J. Infect. 81:e49–e52. doi: 10.1016/j.jinf.2020.04.023
Zhang, J.-F., Yan, K., Ye, H.-H., Lin, J., Zheng, J.-J., and Cai, T. (2020). SARS-
CoV-2 turned positive in a discharged patient with COVID-19 arouses concern
regarding the present standards for discharge. Int. J. Infect. Dis. 97, 212–214.
doi: 10.1016/j.ijid.2020.03.007
Zhang, M., Zhou, L., Wang, J., Wang, K., Wang, Y., Pan, X., et al. (2020).
The nervous system-A new territory being explored of SARS-CoV-2. J. Clin.
Neurosci. 82(Pt A):87–92. doi: 10.1016/j.jocn.2020.10.056
Zhang, R. Z., Deng, W., He, J., Song, Y. Y., Qian, C. F., Yu, Q., et al. (2020). Case
Report: recurrence of positive SARS-CoV-2 results in patients recovered from
COVID-19. Front. Med. 7:585485. doi: 10.3389/fmed.2020.585485
Zhao, W., Wang, Y., Tang, Y., Zhao, W., Fan, Y., Liu, G., et al.
(2020). Characteristics of children with reactivation of SARS-CoV-
2 infection after hospital discharge. Clin. Pediatr. (Phila). 59, 929–932.
doi: 10.1177/0009922820928057
Zheng, K. I., Wang, X. B., Jin, X. H., Liu, W. Y., Gao, F., Chen, Y. P., et al. (2020).
A case series of recurrent viral RNA positivity in recovered COVID-19 Chinese
patients. J. Gen. Intern. Med. 35, 2205–2206. doi: 10.1007/s11606-020-05822-1
Zhong, Z. F., Huang, J., Yang, X., Peng, J. L., Zhang, X. Y., Hu, Y., et al.
(2020). Epidemiological and clinical characteristics of COVID-19 patients
in Hengyang, Hunan Province, China. World J. Clin. Cases 8, 2554–2565.
doi: 10.12998/wjcc.v8.i12.2554
Zhou, H., Fu, L., Jin, Y., Shao, J., Zhang, S., Zheng, N., et al. (2020). Clinical features
of COVID-19 convalescent patients with re-positive nucleic acid detection. J.
Clin. Lab. Anal. 34:e23392. doi: 10.1002/jcla.23392
Zhou, L., Xu, Z., Castiglione, G. M., Soiberman, U. S., Eberhart, C. G., and Duh,
E. J. (2020). ACE2 and TMPRSS2 are expressed on the human ocular surface,
suggesting susceptibility to SARS-CoV-2 infection. Ocul. Surf. 18, 537–544.
doi: 10.1016/j.jtos.2020.06.007
Zhou, X., Zhou, J., and Zhao, J. (2020). Recurrent pneumonia in a patient
with new coronavirus infection after discharge from hospital for
insufficient antibody production: a case report. BMC Infect. Dis. 20:500.
doi: 10.1186/s12879-020-05231-z
Zhou, Y., Fu, B., Zheng, X., et al. (2020). Pathogenic T cells and inflammatory
monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci.
Rev. 13: nwaa041. doi: 10.1093/nsr/nwaa041
Zubair, A. S., McAlpine, L. S., Gardin, T., Farhadian, S., Kuruvilla, D. E., and
Spudich, S. (2019). Neuropathogenesis and neurologic manifestations of the
Frontiers in Human Neuroscience | www.frontiersin.org 14 August 2021 | Volume 15 | Article 666468
Zaffina et al. Occupational Case of NeuroCovid-19 Recurrence
coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol.
77, 1018–1027. doi: 10.1001/jamaneurol.2020.2065
Author Disclaimer: As for FG, Medical Director of the Italian Ministry of Health,
the opinion and contents expressed in the study are the sole responsibility of the
author, and they are not attributable in any way to the institutional and functional
positions held by the same at the Italian Ministry of Health (Article 12, paragraph
6, of the Code of Conduct of the Italian Ministry of Health, adopted with DM
March 6, 2015 and later).
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Zaffina, Lanteri, Gilardi, Garbarino, Santoro, Vinci, Carsetti,
Scorpecci, Raponi, Magnavita and Camisa. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Human Neuroscience | www.frontiersin.org 15 August 2021 | Volume 15 | Article 666468
